Half-year report · HY
4574.TEDINET S100YVYD
Period2026-01-01 → 2026-06-30
Filed2026-08-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.6bn | 2026-01-01 → 2026-06-30 | Cons. | Net sales |
| Revenue | ¥6.4bn | 2025-01-01 → 2025-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.4bn | 2025-01-01 → 2025-06-30 | Cons. | Net sales |
| Operating income | ¥17m | 2026-01-01 → 2026-06-30 | Cons. | Operating income |
| Operating income | ¥46m | 2025-01-01 → 2025-06-30 | Cons. | Operating income |
| Ordinary income | ¥41m | 2026-01-01 → 2026-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥482m | 2025-01-01 → 2025-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥20m | 2025-01-01 → 2025-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥40m | 2026-01-01 → 2026-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥382m | 2025-01-01 → 2025-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥44m | 2026-01-01 → 2026-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥923m | 2025-01-01 → 2025-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥279m | 2025-01-01 → 2025-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥44m | 2026-01-01 → 2026-06-30 | Cons. | Profit loss |
| Net income | ¥279m | 2025-01-01 → 2025-06-30 | Cons. | Profit loss |
| Total assets | ¥11.1bn | at 2026-06-30 | Cons. | Assets |
| Total assets | ¥12.3bn | at 2025-12-31 | Cons. | Assets |
| Total assets | ¥11.7bn | at 2025-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥2.7bn | at 2026-06-30 | Cons. | Liabilities |
| Total liabilities | ¥3.8bn | at 2025-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥8.4bn | at 2026-06-30 | Cons. | Net assets |
| Net assets / equity | ¥8.5bn | at 2025-12-31 | Cons. | Net assets |
| Net assets / equity | ¥7.9bn | at 2025-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.7bn | at 2026-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥4.3bn | at 2025-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.7bn | at 2026-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.3bn | at 2025-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.1bn | at 2025-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.5bn | at 2024-12-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥66m | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥814m | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥61m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥685m | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥142m | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥295m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥853m | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.2bn | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥684m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥0.89 | 2026-01-01 → 2026-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥169.51 | 2025-01-01 → 2025-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥5.57 | 2025-01-01 → 2025-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 76.0% | at 2026-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 69.4% | at 2025-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.1% | at 2025-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 26
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2026-01-01 → 2026-06-30 | ¥2m |
| Otherother segments | revenue external | 2026-01-01 → 2026-06-30 | ¥2m |
| Otherother segments | segment profit | 2026-01-01 → 2026-06-30 | −¥14m |
| Reconciling Itemsreconciling | segment profit | 2026-01-01 → 2026-06-30 | −¥433m |
| Infection Control Businessreportable segment | revenue | 2026-01-01 → 2026-06-30 | ¥111m |
| Infection Control Businessreportable segment | revenue external | 2026-01-01 → 2026-06-30 | ¥111m |
| Infection Control Businessreportable segment | segment profit | 2026-01-01 → 2026-06-30 | −¥92m |
| Pharmaceuticals Businessreportable segment | revenue | 2026-01-01 → 2026-06-30 | ¥2.5bn |
| Pharmaceuticals Businessreportable segment | revenue external | 2026-01-01 → 2026-06-30 | ¥2.5bn |
| Pharmaceuticals Businessreportable segment | segment profit | 2026-01-01 → 2026-06-30 | ¥557m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2026-01-01 → 2026-06-30 | ¥2.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2026-01-01 → 2026-06-30 | ¥2.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2026-01-01 → 2026-06-30 | ¥450m |
| Otherother segments | revenue | 2025-01-01 → 2025-06-30 | ¥2m |
| Otherother segments | revenue external | 2025-01-01 → 2025-06-30 | ¥2m |
| Otherother segments | segment profit | 2025-01-01 → 2025-06-30 | −¥7m |
| Reconciling Itemsreconciling | segment profit | 2025-01-01 → 2025-06-30 | −¥396m |
| Infection Control Businessreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥203m |
| Infection Control Businessreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥203m |
| Infection Control Businessreportable segment | segment profit | 2025-01-01 → 2025-06-30 | −¥151m |
| Pharmaceuticals Businessreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥2.2bn |
| Pharmaceuticals Businessreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥2.2bn |
| Pharmaceuticals Businessreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥601m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-01-01 → 2025-06-30 | ¥2.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-01-01 → 2025-06-30 | ¥2.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-01-01 → 2025-06-30 | ¥443m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 499
| Item | Context | Value | Unit |
|---|---|---|---|
| Name major shareholders | InterimInstant_No3MajorShareholdersMember | Original text (Japanese)柴田 仁 | |
| Address major shareholders | InterimInstant_No3MajorShareholdersMember | Original text (Japanese)大阪府吹田市 | |
| Name major shareholders | InterimInstant_No4MajorShareholdersMember | Text · Plus | |
| Address major shareholders | InterimInstant_No4MajorShareholdersMember | Text · Plus | |
| Name major shareholders | InterimInstant_No5MajorShareholdersMember | Original text (Japanese)日本マスタートラスト信託銀行株式会社（信託口） | |
| Address major shareholders | InterimInstant_No5MajorShareholdersMember | Original text (Japanese)東京都港区赤坂１丁目８番１号赤坂インターシティAIR | |
| Name major shareholders | InterimInstant_No6MajorShareholdersMember | Original text (Japanese)ZONGYI SOLAR POWER(LUXEMBOURG)（常任代理人 シティバンク、エヌ・エイ東京支店） | |
| Address major shareholders | InterimInstant_No6MajorShareholdersMember | Original text (Japanese)560A, RUE DE NEUDORF, L-2220, LUXEMBOURG（東京都新宿区新宿６丁目27番30号） | |
| Name major shareholders | InterimInstant_No7MajorShareholdersMember | Original text (Japanese)柴田 晃宏 | |
| Address major shareholders | InterimInstant_No7MajorShareholdersMember | Original text (Japanese)奈良県生駒市 | |
| Name major shareholders | InterimInstant_No8MajorShareholdersMember | Original text (Japanese)興和株式会社 | |
| Address major shareholders | InterimInstant_No8MajorShareholdersMember | Original text (Japanese)愛知県名古屋市中区錦３丁目６－29 | |
| Name major shareholders | InterimInstant_No9MajorShareholdersMember | Original text (Japanese)柴田 穣 | |
| Address major shareholders | InterimInstant_No9MajorShareholdersMember | Original text (Japanese)大阪府吹田市 | |
| Name major shareholders | InterimInstant_No10MajorShareholdersMember | Original text (Japanese)アース製薬株式会社 | |
| Address major shareholders | InterimInstant_No10MajorShareholdersMember | Original text (Japanese)東京都千代田区神田司町２丁目12－１ | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | InterimInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | InterimInstant_SharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | InterimInstant_SharesWithFullVotingRightsOtherMember | － | |
| Description issued shares voting rights | InterimInstant_SharesLessThanOneUnitMember | － | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | InterimInstant_Row1Member | Original text (Japanese)大幸薬品株式会社 | |
| Address of shareholder treasury shares etc | InterimInstant_Row1Member | Original text (Japanese)大阪府吹田市内本町三丁目34番14号 | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | InterimDuration | Text · Plus | |
| Type1 semi annual consolidated financial statements financial information | InterimDuration | Text · Plus | |
| Note on independent audit financial information | InterimDuration | Text · Plus | |
| Type1 semi annual consolidated balance sheet (text) | InterimDuration | Text · Plus | |
| Type1 semi annual consolidated statement of income (text) | InterimDuration | Text · Plus | |
| Type1 semi annual consolidated statement of comprehensive income (text) | InterimDuration | Text · Plus | |
| Type1 semi annual consolidated statement of cash flows (text) | InterimDuration | Text · Plus | |
| Major components of selling general and administrative expenses (text) | InterimDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | InterimDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1InterimDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1InterimDuration | Text · Plus | |
| Notes regarding dividend (text) | InterimDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | InterimDuration | Text · Plus | |
| Notes segment information etc type1 semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1InterimDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1InterimDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | InterimDuration | Text · Plus | |
| Notes revenue recognition semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Notes per share information semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Notes significant events after reporting period semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | InterimDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |